IOBT - Recent IPO IO Biotech up 8% as quiet period ends

IO Biotech (IOBT +7.9%), which had its IPO earlier this month, has ended its quiet period today with an upward swing. However, shares are still well below the IPO price of $14 a share. IO's lead candidate, IO102-IO103, is in phase 3 in combination with a PD1 monoclonal antibody as a first-line melanoma treatment. Seeking Alpha contributor Avisol Capital Partners says that the company's treatments are based on a unique platform technology that recognizes and eliminates immunosuppressive cells and tumor cells.

For further details see:

Recent IPO IO Biotech up 8% as quiet period ends